医药生物行业跟踪周报：抗抑郁新药进入收获期，关注吉贝尔、翰森制药、绿叶制药等

Investment Rating - The report maintains an "Overweight" rating for the innovative drug sector, highlighting the approval of new drugs and their potential market impact [17]. Core Insights - The depression market is identified as a significant opportunity, with a global patient population of approximately 280 million, representing about 3.8% of the global population. In China, the lifetime prevalence of depression is reported at 6.8%, with around 95 million patients [36][47]. - The report emphasizes the urgent need for new antidepressant drugs to address unmet treatment needs, as existing medications often have slow onset and poor patient adherence [40][47]. - Companies with a focus on developing new antidepressants, such as JiBeier, Green Leaf Pharmaceutical, and HanSen Pharmaceutical, are recommended for investment consideration [40][47]. Summary by Sections 1. Market Overview - The global antidepressant market was valued at approximately $14.5 billion in 2022 and is projected to reach $17.6 billion by 2030, with a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 [37]. 2. Drug Development Landscape - The report outlines the current landscape of antidepressant medications, including SSRIs and SNRIs, which are widely recommended as first-line treatments. However, these drugs face challenges such as delayed efficacy and adherence issues [40][47]. 3. Company Focus - The report highlights several companies in various sectors, including: - Innovative drugs: Innovent Biologics, Hengrui Medicine, and others [19]. - Traditional Chinese medicine: Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and others [19]. - CXO and research services: WuXi AppTec, and others [19]. - High-end formulations: Renfu Pharmaceutical, Enhua Pharmaceutical, and others [19]. - Medical services: Aier Eye Hospital, and others [19].